Aankondiging • Jul 20
Divi's Laboratories Limited to Report Q1, 2027 Results on Aug 01, 2026 Divi's Laboratories Limited announced that they will report Q1, 2027 results at 9:08 AM, Indian Standard Time on Aug 01, 2026 Upcoming Dividend • Jul 17
Upcoming dividend of ₹30.00 per share Eligible shareholders must have bought the stock before 24 July 2026. Payment date: 09 September 2026. Payout ratio is a comfortable 31% but the company is paying out more than the cash it is generating. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.5%). In line with average of industry peers (0.4%). Declared Dividend • May 27
Dividend of ₹30.00 announced Dividend of ₹30.00 is the same as last year. Ex-date: 24th July 2026 Payment date: 9th September 2026 Dividend yield will be 0.4%, which is lower than the industry average of 0.6%. Sustainability & Growth Dividend is covered by earnings (31% earnings payout ratio) but not covered by cash flows (365% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 60% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Aankondiging • May 26
Divi's Laboratories Limited announces Annual dividend, payable on September 09, 2026 Divi's Laboratories Limited announced Annual dividend of INR 30.0000 per share payable on September 09, 2026, ex-date on July 24, 2026 and record date on July 24, 2026. Aankondiging • May 25
Divi's Laboratories Limited, Annual General Meeting, Aug 10, 2026 Divi's Laboratories Limited, Annual General Meeting, Aug 10, 2026. Reported Earnings • May 24
Full year 2026 earnings: Revenues and EPS in line with analyst expectations Full year 2026 results: EPS: ₹96.75 (up from ₹82.53 in FY 2025). Revenue: ₹105.6b (up 13% from FY 2025). Net income: ₹25.7b (up 17% from FY 2025). Profit margin: 24% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 25% per year. Aankondiging • May 14
Divi's Laboratories Limited to Report Q4, 2026 Results on May 23, 2026 Divi's Laboratories Limited announced that they will report Q4, 2026 results at 9:08 AM, Indian Standard Time on May 23, 2026 Reported Earnings • Feb 12
Third quarter 2026 earnings: EPS misses analyst expectations Third quarter 2026 results: EPS: ₹21.98 (down from ₹22.20 in 3Q 2025). Revenue: ₹26.0b (up 12% from 3Q 2025). Net income: ₹5.83b (down 1.0% from 3Q 2025). Profit margin: 22% (down from 25% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.1%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Jan 30
Divi's Laboratories Limited to Report Q3, 2026 Results on Feb 11, 2026 Divi's Laboratories Limited announced that they will report Q3, 2026 results on Feb 11, 2026 Reported Earnings • Nov 08
Second quarter 2026 earnings released: EPS: ₹25.97 (vs ₹19.20 in 2Q 2025) Second quarter 2026 results: EPS: ₹25.97 (up from ₹19.20 in 2Q 2025). Revenue: ₹27.2b (up 16% from 2Q 2025). Net income: ₹6.89b (up 35% from 2Q 2025). Profit margin: 25% (up from 22% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Oct 27
Divi's Laboratories Limited to Report Q2, 2026 Results on Nov 07, 2025 Divi's Laboratories Limited announced that they will report Q2, 2026 results on Nov 07, 2025 Aankondiging • Jul 26
Divi's Laboratories Limited to Report Q1, 2026 Results on Aug 06, 2025 Divi's Laboratories Limited announced that they will report Q1, 2026 results on Aug 06, 2025 Upcoming Dividend • Jul 18
Upcoming dividend of ₹30.00 per share Eligible shareholders must have bought the stock before 25 July 2025. Payment date: 10 September 2025. Payout ratio is a comfortable 36% but the company is paying out more than the cash it is generating. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.2%). In line with average of industry peers (0.4%). Reported Earnings • Jul 15
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: ₹82.53 (up from ₹60.27 in FY 2024). Revenue: ₹93.6b (up 19% from FY 2024). Net income: ₹21.9b (up 37% from FY 2024). Profit margin: 23% (up from 20% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings. Reported Earnings • May 23
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: ₹82.53 (up from ₹60.27 in FY 2024). Revenue: ₹93.6b (up 19% from FY 2024). Net income: ₹21.9b (up 37% from FY 2024). Profit margin: 23% (up from 20% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.7%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Declared Dividend • May 21
Dividend of ₹30.00 announced Dividend of ₹30.00 is the same as last year. Ex-date: 25th July 2025 Payment date: 10th September 2025 Dividend yield will be 0.5%, which is lower than the industry average of 0.6%. Sustainability & Growth Dividend is covered by earnings (50% earnings payout ratio) but not covered by cash flows (168% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 74% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Aankondiging • May 20
Divi's Laboratories Limited announces Annual dividend, payable on September 10, 2025 Divi's Laboratories Limited announced Annual dividend of INR 30.0000 per share payable on September 10, 2025, ex-date on July 25, 2025 and record date on July 25, 2025. Aankondiging • May 19
Divi's Laboratories Limited, Annual General Meeting, Aug 11, 2025 Divi's Laboratories Limited, Annual General Meeting, Aug 11, 2025. Aankondiging • May 10
Divi's Laboratories Limited to Report Q4, 2025 Results on May 17, 2025 Divi's Laboratories Limited announced that they will report Q4, 2025 results at 9:08 AM, Indian Standard Time on May 17, 2025 Reported Earnings • Feb 04
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: EPS: ₹22.20 (up from ₹13.50 in 3Q 2024). Revenue: ₹23.2b (up 25% from 3Q 2024). Net income: ₹5.89b (up 65% from 3Q 2024). Profit margin: 25% (up from 19% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 17%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Aankondiging • Feb 03
Divi's Laboratories Limited Appoints Manoranjan Jasti as Chief Information Officer Divi's Laboratories Limited announced that Mr. Manoranjan Jasti serving as Chief Information Officer of the Company has been designated as Senior Management Personnel of the Company effective from February 03, 2025. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors, in its meeting held on February 03, 2025, have granted approval for the terms of appointment of Mr. Manoranjan Jasti, with the specific categorization as Senior Management Personnel. Mr. Manoranjan Jasti did his Masters in Computer Networks from Middlesex University, UK in the year 2001. He holds Bachelor of Engineering in Electronics and Communication from Madras University, Chennai. He started his career as Programmer at Unisys Corporation, Uxbridge, London in 2001 and worked for multiple MNC companies in UK between 2001 to 2006. He has joined ValueLabs, Hyderabad as Senior Software Engineer in 2006 and worked there until 2017. He has joined the Company in the year 2017 as Assistant General Manager (IT) and currently serving as the Chief Information Officer of the Company overseeing the IT operations of the Company. He is responsible for overseeing all information technology (IT) aspects of a company, including developing and implementing strategic IT plans, managing data systems, ensuring data security, supporting research and development processes, and aligning technology with business goals. Aankondiging • Jan 23
Divi's Laboratories Limited to Report Q3, 2025 Results on Feb 03, 2025 Divi's Laboratories Limited announced that they will report Q3, 2025 results on Feb 03, 2025 Recent Insider Transactions • Dec 03
Insider recently sold ₹30m worth of stock On the 26th of November, Madhusudana Divi sold around 5k shares on-market at roughly ₹6,071 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹963m more than they bought in the last 12 months. Price Target Changed • Nov 11
Price target increased by 7.8% to ₹4,988 Up from ₹4,627, the current price target is an average from 26 analysts. New target price is 15% below last closing price of ₹5,894. Stock is up 68% over the past year. The company is forecast to post earnings per share of ₹77.22 for next year compared to ₹60.27 last year. Reported Earnings • Nov 10
Second quarter 2025 earnings released: EPS: ₹19.20 (vs ₹13.11 in 2Q 2024) Second quarter 2025 results: EPS: ₹19.20 (up from ₹13.11 in 2Q 2024). Revenue: ₹24.4b (up 28% from 2Q 2024). Net income: ₹5.10b (up 47% from 2Q 2024). Profit margin: 21% (up from 18% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in India. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Aankondiging • Oct 29
Divi's Laboratories Limited to Report Q2, 2025 Results on Nov 09, 2024 Divi's Laboratories Limited announced that they will report Q2, 2025 results at 12:08 PM, Indian Standard Time on Nov 09, 2024 Recent Insider Transactions • Aug 30
Chief Technologist - PDSC recently sold ₹9.8m worth of stock On the 26th of August, M. Babu sold around 2k shares on-market at roughly ₹4,905 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹59m. Insiders have been net sellers, collectively disposing of ₹843m more than they bought in the last 12 months. Recent Insider Transactions • Aug 14
Insider recently sold ₹59m worth of stock On the 7th of August, Madhusudana Divi sold around 12k shares on-market at roughly ₹4,888 per share. This transaction amounted to 5.9% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹238m. Insiders have been net sellers, collectively disposing of ₹937m more than they bought in the last 12 months. Aankondiging • Aug 13
Divi's Laboratories Limited Declares Dividend for the Financial Year Ended March 31, 2024 Divi's Laboratories Limited announced at the AGM held on August 12, 2024, to declare dividend of INR 30/- per equity share of face value INR 2/- each (i.e. @ 1,500%) for the financial year ended March 31, 2024. Price Target Changed • Aug 05
Price target increased by 10% to ₹4,332 Up from ₹3,922, the current price target is an average from 26 analysts. New target price is 10% below last closing price of ₹4,829. Stock is up 23% over the past year. The company is forecast to post earnings per share of ₹77.32 for next year compared to ₹60.27 last year. Upcoming Dividend • Jul 26
Upcoming dividend of ₹30.00 per share Eligible shareholders must have bought the stock before 02 August 2024. Payment date: 11 September 2024. Payout ratio is a comfortable 50% but the company is paying out more than the cash it is generating. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.1%). In line with average of industry peers (0.6%). Aankondiging • Jul 25
Divi's Laboratories Limited to Report Q1, 2025 Results on Aug 03, 2024 Divi's Laboratories Limited announced that they will report Q1, 2025 results at 12:08 PM, Indian Standard Time on Aug 03, 2024 Reported Earnings • Jul 16
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: EPS: ₹60.27 (down from ₹68.71 in FY 2023). Revenue: ₹78.5b (up 1.0% from FY 2023). Net income: ₹16.0b (down 12% from FY 2023). Profit margin: 20% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.5%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Aankondiging • Jun 22
Divi's Laboratories Limited Announces Board and Committee Changes Divi's Laboratories Limited announced that Mr. K.V.K Seshavataram has completed his second term as an Independent Director and consequently ceased to be a Director of the Company with effect from the close of business hours on June 22, 2024. Consequent to the cessation, Mr. K.V.K Seshavataram will also cease to be Chairman/Member of the following Board Committees of the Company from June 22, 2024: 1. Audit Committee Chaiman 2. Stakeholders Relationship Committee - Member. Further, the Board has designated Mr. K.V. Chowdary, Independent Director and member of Audit Committee of the Company, as Chairman of the Audit Committee with effect from June 23, 2024. Recent Insider Transactions • Jun 20
Insider recently sold ₹46m worth of stock On the 14th of June, Nimmagadda Anirudh sold around 10k shares on-market at roughly ₹4,597 per share. This transaction amounted to 3.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹238m. Insiders have been net sellers, collectively disposing of ₹896m more than they bought in the last 12 months. Recent Insider Transactions • Jun 01
Insider recently sold ₹238m worth of stock On the 29th of May, Madhusudana Divi sold around 55k shares on-market at roughly ₹4,336 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹794m more than they bought in the last 12 months. Declared Dividend • May 29
Dividend of ₹30.00 announced Dividend of ₹30.00 is the same as last year. Ex-date: 2nd August 2024 Payment date: 11th September 2024 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (44% earnings payout ratio) but not covered by cash flows (100% cash payout ratio). The dividend has increased by an average of 15% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 82% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Price Target Changed • May 28
Price target increased by 11% to ₹3,806 Up from ₹3,442, the current price target is an average from 26 analysts. New target price is 13% below last closing price of ₹4,391. Stock is up 27% over the past year. The company is forecast to post earnings per share of ₹58.25 for next year compared to ₹68.69 last year. Aankondiging • May 25
Divi's Laboratories Limited Recommends A Final Dividend for the Financial Year 2023-24 Divi's Laboratories Limited at its board meeting, held on May 25, 2024, Recommended a final dividend of INR 30/- (i.e. 1,500%) per equity share of face value INR 2/- each for the financial year 2023-24, subject to the approval of the members at the upcoming 34th Annual General Meeting (AGM). The dividend shall be paid within specified timelines from the conclusion of the AGM. The 34th AGM of the Members of the Company will be held on August 12, 2024. The record date for the purpose of the payment of dividend is August 02, 2024. Aankondiging • May 17
Divi's Laboratories Limited to Report Q4, 2024 Results on May 25, 2024 Divi's Laboratories Limited announced that they will report Q4, 2024 results at 12:08 PM, Indian Standard Time on May 25, 2024 Aankondiging • Apr 05
Divi's Laboratories Limited Approves Appointment of Dr. S. Devendra Rao as Whole-Time Director (Manufacturing) Divi's Laboratories Limited by Postal Ballot on April 04, 2024 approved appointment of Dr. S. Devendra Rao as Whole-time Director, designated as `Whole-time Director (Manufacturing)' of the Company and approval of the remuneration payable to him. Recent Insider Transactions • Apr 02
Insider recently sold ₹24m worth of stock On the 28th of March, Madhusudana Divi sold around 7k shares on-market at roughly ₹3,394 per share. This transaction amounted to 2.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹112m. Insiders have been net sellers, collectively disposing of ₹543m more than they bought in the last 12 months. Recent Insider Transactions • Feb 19
Chief Technologist recently sold ₹56m worth of stock On the 14th of February, P. Rao sold around 15k shares on-market at roughly ₹3,715 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹59m. Insiders have been net sellers, collectively disposing of ₹409m more than they bought in the last 12 months. Reported Earnings • Feb 11
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: ₹13.50 (up from ₹11.56 in 3Q 2023). Revenue: ₹19.5b (up 14% from 3Q 2023). Net income: ₹3.58b (up 17% from 3Q 2023). Profit margin: 18% (in line with 3Q 2023). Revenue missed analyst estimates by 6.9%. Earnings per share (EPS) also missed analyst estimates by 14%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Aankondiging • Jan 31
Divi's Laboratories Limited to Report Q3, 2024 Results on Feb 10, 2024 Divi's Laboratories Limited announced that they will report Q3, 2024 results on Feb 10, 2024 Recent Insider Transactions • Jan 02
Insider recently sold ₹59m worth of stock On the 28th of December, Madhusudana Divi sold around 15k shares on-market at roughly ₹3,905 per share. This transaction amounted to 5.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹348m more than they bought in the last 12 months. Recent Insider Transactions • Nov 18
Non-Executive Independent Director recently sold ₹1.4m worth of stock On the 15th of November, Gangavarapu Kumar sold around 400 shares on-market at roughly ₹3,490 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹100m. Insiders have been net sellers, collectively disposing of ₹273m more than they bought in the last 12 months. Reported Earnings • Nov 07
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: ₹13.11 (down from ₹18.34 in 2Q 2023). Revenue: ₹19.1b (up 2.9% from 2Q 2023). Net income: ₹3.48b (down 30% from 2Q 2023). Profit margin: 18% (down from 27% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 15%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 2% per year. Aankondiging • Oct 28
Divi's Laboratories Limited to Report Q2, 2024 Results on Nov 06, 2023 Divi's Laboratories Limited announced that they will report Q2, 2024 results on Nov 06, 2023 Recent Insider Transactions • Sep 22
Insider recently sold ₹3.3m worth of stock On the 15th of September, K. Sridevi sold around 870 shares on-market at roughly ₹3,820 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹100m. Insiders have been net sellers, collectively disposing of ₹294m more than they bought in the last 12 months. Recent Insider Transactions • Sep 07
Chief Technologist recently sold ₹2.9m worth of stock On the 4th of September, M. Babu sold around 800 shares on-market at roughly ₹3,629 per share. This transaction amounted to 3.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹100m. Insiders have been net sellers, collectively disposing of ₹282m more than they bought in the last 12 months. Aankondiging • Aug 30
Divi's Laboratories Limited Declares Dividend for the Financial Year Ended March 31, 2023 Divi's Laboratories Limited at its 33rd Annual General Meeting held on August 28, 2023, declared dividend of INR 30/- per equity share of face value INR 2/- each (i.e., @ 1500%) for the financial year ended March 31, 2023. Aankondiging • Aug 29
Divi's Laboratories Limited Informs Resignations of Directors Divi's Laboratories Limited informed that Sri Madhusudana Rao Divi expressed his intention to retire as a Director as well as Whole-time Director of the Company in view of his age and health situation, and submitted his resignation with immediate effect to the same. A copy of his resignation letter isenclosed herewith. The Board of Directors vide its resolution dated August 28, 2023 have approved his retirement and accepted the resignation letter with immediate effect i.e. from August 28, 2023. Price Target Changed • Aug 17
Price target increased by 7.3% to ₹3,325 Up from ₹3,098, the current price target is an average from 23 analysts. New target price is 9.2% below last closing price of ₹3,660. Stock is down 2.3% over the past year. The company is forecast to post earnings per share of ₹71.14 for next year compared to ₹68.69 last year. New Risk • Aug 16
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 20% Last year net profit margin: 34% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (20% net profit margin). Significant insider selling over the past 3 months (₹50m sold). Board Change • Aug 14
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Non-Executive Independent Director Kosaraju Chowdary was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Aankondiging • Aug 05
Divi's Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023 Divi's Laboratories Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Reported Earnings • Aug 04
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: ₹68.69 (down from ₹112 in FY 2022). Revenue: ₹77.7b (down 13% from FY 2022). Net income: ₹18.2b (down 38% from FY 2022). Profit margin: 24% (down from 33% in FY 2022). Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) missed analyst estimates by 3.7%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. New Risk • Jul 07
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹50m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. This is currently the only risk that has been identified for the company. Aankondiging • Jul 04
Divi's Laboratories Limited, Annual General Meeting, Aug 28, 2023 Divi's Laboratories Limited, Annual General Meeting, Aug 28, 2023, at 10:00 Indian Standard Time. Recent Insider Transactions • May 29
Insider recently sold ₹3.4m worth of stock On the 25th of May, Y. Devi sold around 995 shares on-market at roughly ₹3,383 per share. This transaction amounted to 4.2% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹142m more than they bought in the last 12 months. Aankondiging • May 21
Divi's Laboratories Limited Recommends a Dividend for the Financial Year 2022-23 Divi's Laboratories Limited at its board meeting held on May 20, 2023, recommended a Dividend of INR 30 (i.e. 1,500%) per equity share of face value INR 2 each for the financial year 2022-23, subject To Approve the members at the upcoming 33rd Annual General Meeting (AGM). Reported Earnings • May 20
Full year 2023 earnings released: EPS: ₹68.69 (vs ₹112 in FY 2022) Full year 2023 results: EPS: ₹68.69 (down from ₹112 in FY 2022). Revenue: ₹81.1b (down 9.5% from FY 2022). Net income: ₹18.2b (down 38% from FY 2022). Profit margin: 23% (down from 33% in FY 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Aankondiging • May 13
Divi's Laboratories Limited to Report Q4, 2023 Results on May 20, 2023 Divi's Laboratories Limited announced that they will report Q4, 2023 results on May 20, 2023 Recent Insider Transactions • Apr 01
Insider recently sold ₹2.0m worth of stock On the 28th of March, Ancha Rao sold around 700 shares on-market at roughly ₹2,798 per share. This transaction amounted to 6.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹28m. Insiders have been net sellers, collectively disposing of ₹138m more than they bought in the last 12 months. Recent Insider Transactions • Mar 17
Global Quality Head recently sold ₹2.3m worth of stock On the 13th of March, Y. T. Prasad sold around 815 shares on-market at roughly ₹2,795 per share. This transaction amounted to 1.5% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹28m. Insiders have been net sellers, collectively disposing of ₹139m more than they bought in the last 12 months. Recent Insider Transactions • Mar 10
Global Quality Head recently sold ₹2.8m worth of stock On the 6th of March, Y. T. Prasad sold around 1k shares on-market at roughly ₹2,850 per share. This transaction amounted to 1.8% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹28m. Insiders have been net sellers, collectively disposing of ₹137m more than they bought in the last 12 months. Recent Insider Transactions • Feb 12
Global Quality Head recently sold ₹28m worth of stock On the 8th of February, Y. T. Prasad sold around 10k shares on-market at roughly ₹2,800 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹155m more than they bought in the last 12 months. Price Target Changed • Feb 07
Price target decreased by 14% to ₹3,064 Down from ₹3,549, the current price target is an average from 24 analysts. New target price is 11% above last closing price of ₹2,749. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₹71.04 for next year compared to ₹112 last year. Reported Earnings • Feb 05
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: EPS: ₹11.56 (down from ₹33.99 in 3Q 2022). Revenue: ₹17.1b (down 32% from 3Q 2022). Net income: ₹3.07b (down 66% from 3Q 2022). Profit margin: 18% (down from 36% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 34%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Aankondiging • Jan 24
Divi's Laboratories Limited to Report Q3, 2023 Results on Feb 03, 2023 Divi's Laboratories Limited announced that they will report Q3, 2023 results on Feb 03, 2023 Recent Insider Transactions • Dec 16
MD & Executive Director recently sold ₹1.0m worth of stock On the 13th of December, Murali Krishna Divi sold around 300 shares on-market at roughly ₹3,360 per share. This transaction amounted to 7.1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹91m more than they bought in the last 12 months. Recent Insider Transactions • Nov 27
Insider recently sold ₹1.7m worth of stock On the 25th of November, G. Chowdary sold around 500 shares on-market at roughly ₹3,310 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹115m more than they bought in the last 12 months. Recent Insider Transactions • Nov 20
Insider recently sold ₹1.2m worth of stock On the 17th of November, M. Krishna sold around 350 shares on-market at roughly ₹3,295 per share. This transaction amounted to 7.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹120m more than they bought in the last 12 months. Price Target Changed • Nov 16
Price target decreased to ₹3,582 Down from ₹4,013, the current price target is an average from 23 analysts. New target price is 8.9% above last closing price of ₹3,290. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₹83.78 for next year compared to ₹112 last year. Price Target Changed • Nov 10
Price target decreased to ₹3,650 Down from ₹4,013, the current price target is an average from 23 analysts. New target price is 11% above last closing price of ₹3,298. Stock is down 32% over the past year. The company is forecast to post earnings per share of ₹83.95 for next year compared to ₹112 last year. Reported Earnings • Nov 08
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: EPS: ₹18.60 (down from ₹22.84 in 2Q 2022). Revenue: ₹19.3b (down 2.7% from 2Q 2022). Net income: ₹4.94b (down 19% from 2Q 2022). Profit margin: 26% (down from 31% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 23%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 26% per year. Recent Insider Transactions • Sep 30
Insider recently sold ₹1.5m worth of stock On the 27th of September, Radhika Dronavalli sold around 400 shares on-market at roughly ₹3,663 per share. This transaction amounted to 42% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹3.8m. Insiders have been net sellers, collectively disposing of ₹94m more than they bought in the last 12 months. Recent Insider Transactions • Sep 16
Insider recently sold ₹3.7m worth of stock On the 13th of September, Lavu Srinidhi sold around 1k shares on-market at roughly ₹3,701 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹89m more than they bought in the last 12 months. Upcoming Dividend • Aug 04
Upcoming dividend of ₹30.00 per share Eligible shareholders must have bought the stock before 11 August 2022. Payment date: 21 September 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Indian dividend payers (1.7%). In line with average of industry peers (0.7%). Aankondiging • Jul 30
Divi's Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022 Divi's Laboratories Limited announced that they will report Q1, 2023 results on Aug 12, 2022 Reported Earnings • Jul 26
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: ₹112 (up from ₹74.75 in FY 2021). Revenue: ₹89.6b (up 29% from FY 2021). Net income: ₹29.6b (up 49% from FY 2021). Profit margin: 33% (up from 28% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 9.0%. Over the next year, revenue is forecast to grow 1.8%, compared to a 37% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 31% per year. Aankondiging • Jul 06
Divi's Laboratories Limited Recommends Dividend Divi's Laboratories Limited recommended a dividend of INR 30 per equity share of INR 2 each (i.e. 1500%) for the financial year 2021-22, subject To Approve the shareholders at the AGM scheduled to be held on August 22, 2022. Aankondiging • Jul 05
Divi's Laboratories Limited, Annual General Meeting, Aug 22, 2022 Divi's Laboratories Limited, Annual General Meeting, Aug 22, 2022, at 10:00 Indian Standard Time. Recent Insider Transactions • Jul 02
Insider recently sold ₹2.5m worth of stock On the 30th of June, Y. Rao sold around 700 shares on-market at roughly ₹3,585 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹7.3m. Insiders have been net sellers, collectively disposing of ₹102m more than they bought in the last 12 months. Recent Insider Transactions • Jun 11
Insider recently sold ₹7.3m worth of stock On the 8th of June, S. Rao sold around 2k shares on-market at roughly ₹3,510 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹9.1m. Insiders have been net sellers, collectively disposing of ₹234m more than they bought in the last 12 months. Aankondiging • May 24
Divi's Laboratories Limited Recommends A Dividend for the Year 2021-2022 The board of directors of Divi's Laboratories Limited meeting held on May 23, 2022, recommended a Dividend of INR 30 (i.e. 1500%) per equity share of face value INR 2/- each for the financial year 2021-22, subject To Approve the members at the upcoming 32 nd Annual General Meeting (AGM). The dividend shall be credited/warrants thereof dispatched within 30 (thirty) days from the conclusion of the AGM. The AGM date and book closure /record date for the purpose of the payment of dividend will be informed in due course. Price Target Changed • May 24
Price target decreased to ₹4,466 Down from ₹4,804, the current price target is an average from 16 analysts. New target price is 22% above last closing price of ₹3,662. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₹97.81 for next year compared to ₹112 last year. Aankondiging • May 14
Divi's Laboratories Limited to Report Q4, 2022 Results on May 23, 2022 Divi's Laboratories Limited announced that they will report Q4, 2022 results on May 23, 2022 Recent Insider Transactions • Mar 28
Insider recently sold ₹2.7m worth of stock On the 23rd of March, Sandya Chittineni sold around 600 shares on-market at roughly ₹4,545 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹21m. Insiders have been net sellers, collectively disposing of ₹252m more than they bought in the last 12 months. Recent Insider Transactions • Mar 17
Board Member recently sold ₹21m worth of stock On the 10th of March, Madhusudana Divi sold around 5k shares on-market at roughly ₹4,289 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹247m more than they bought in the last 12 months. Recent Insider Transactions • Feb 27
Insider recently bought ₹796k worth of stock On the 24th of February, Manjula Pasumarthy bought around 200 shares on-market at roughly ₹3,980 per share. In the last 3 months, they made an even bigger purchase worth ₹2.5m. Despite this recent purchase, insiders have collectively sold ₹226m more in shares than they bought in the last 12 months. Reported Earnings • Feb 13
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: ₹33.99 (up from ₹17.73 in 3Q 2021). Revenue: ₹24.9b (up 47% from 3Q 2021). Net income: ₹9.02b (up 92% from 3Q 2021). Profit margin: 36% (up from 28% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) also surpassed analyst estimates by 48%. Over the next year, revenue is forecast to grow 14%, compared to a 33% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Dec 20
Insider recently bought ₹1.1m worth of stock On the 16th of December, Y. Rao bought around 229 shares on-market at roughly ₹4,609 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹4.9m. Despite this recent purchase, insiders have collectively sold ₹211m more in shares than they bought in the last 12 months. Reported Earnings • Nov 07
Second quarter 2022 earnings released: EPS ₹22.84 (vs ₹19.57 in 2Q 2021) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2022 results: Revenue: ₹20.1b (up 15% from 2Q 2021). Net income: ₹6.06b (up 17% from 2Q 2021). Profit margin: 30% (in line with 2Q 2021). Recent Insider Transactions • Sep 30
Insider recently sold ₹1.3m worth of stock On the 23rd of September, K. Sreehari sold around 250 shares on-market at roughly ₹5,159 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹12m. Insiders have been net sellers, collectively disposing of ₹348m more than they bought in the last 12 months. Recent Insider Transactions • Aug 14
Insider recently sold ₹12m worth of stock On the 12th of August, Neetu Jasti sold around 3k shares on-market at roughly ₹4,912 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹65m. Insiders have been net sellers, collectively disposing of ₹517m more than they bought in the last 12 months. 
